Adjuvant Therapy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in Patients with Resected Pancreatic Cancer
Overview
- Phase
- Phase 1
- Intervention
- Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
- Conditions
- Pancreatic Cancer
- Sponsor
- Sichuan University
- Enrollment
- 43
- Locations
- 1
- Primary Endpoint
- Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
Investigators
Zhen-Yu Ding
Professor
Sichuan University
Eligibility Criteria
Inclusion Criteria
- •Age ≥18 years and age ≤75 years.
- •ECOG score 0-
- •Patients with histologically confirmed pancreatic ductal adenocarcinoma, R0 resection, stage I-III, not receiving neoadjuvant therapy.
- •Adequate bone marrow and organ function:
- •Patients of childbearing potential must take appropriate precautions prior to enrollment and during the study.
- •Signed informed consent.
- •Ability to comply with the study protocol and follow-up.
Exclusion Criteria
- •Received antitumor chemotherapy, radiation therapy, or immunotherapy within 2 weeks prior to first vaccination.
- •The patient has a history of other tumors, except for cervical cancer in situ, treated squamous cell carcinoma or urothelial tumors (Ta and TIS), or other malignancies that have been treated with curative intent (at least 5 years prior to enrollment).
- •Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, symptomatic congestive heart failure, unstable angina, arrhythmias.
- •HIV infection or active hepatitis B (HBV DNA≥500IU/ml), hepatitis C.
- •Uncontrolled coronary artery disease or asthma, uncontrolled cerebrovascular disease, or other conditions deemed ineligible by the investigator.
- •Uncontrollable comorbidities, including but not limited to active bacterial or fungal infections, congestive heart failure, unstable angina, arrhythmias, etc;
- •Patients with autoimmune diseases or immunodeficiencies being treated with immunosuppressive drugs.
- •Pregnant or lactating women.
- •Vaccination with other preventive vaccines within 4 weeks before the first administration or planned during the study period, including within 8 weeks after the last vaccination.
- •Those who have had a severe allergic reaction to vaccines for other infectious diseases in the past.
Arms & Interventions
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
(1)8 cycles of Gemcitabine +capecitabine (Gemcitabine d1,8 ,Capecitabine d1-14 q3w）；（2） two 200 mg intravenous dose of tislelizumab (d1,q3w)（3）five intravenous doses of neoantigen vaccines given as priming doses(d1,8,22,36,50）and two booster dose(d80,d110)
Intervention: Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
Outcomes
Primary Outcomes
Incidence of Treatment-Related Adverse Events [Safety and Tolerability]
Time Frame: 3 months after the last administration of neoantigen vaccine
Defined by treatment-related adverse events as assessed by CTCAE v4.0
18-month RFS
Time Frame: through study completion, an average of 2 year
defined recurrence as new lesions on the basis of response evaluation criteria in solid tumours (v.1.1), and RFS from either the date of surgery (RFS) or from the date of the last neoantigen vaccine priming dose to the date of recurrence or death, whichever occurred first.
Secondary Outcomes
- 18-month OS(through study completion, an average of 3 year)